High-performance computing is no longer an optional infrastructure investment for drug discovery — it is the primary lever separating biotech organizations that compress R&D timelines from those still running conventional wet-lab-first pipelines. The return on investment case for HPC in pharma and biotech has strengthened considerably as compute costs have fallen, cloud HPC has matured, and AI-driven simulation workloads have become standard across the pipeline. This guide breaks down how biotech and pharmaceutical companies should evaluate HPC ROI, which workloads generate the strongest returns, and what the current data says about HPC-driven cost reduction and timeline acceleration in drug discovery.
The financial pressure on drug development is well-documented. According to Deloitte’s 2024 analysis, the average cost for a large pharmaceutical company to bring a single asset to market now sits at $2.23 billion, up from $2.12 billion the year prior. Meanwhile, Phase 1 drug success rates have dropped to 6.7%, down from roughly 10% a decade ago. HPC addresses both problems directly — reducing the cost and time of early-stage candidate identification while improving the quality of leads that enter expensive clinical stages.
What HPC Actually Does in a Drug Discovery Pipeline
Understanding the ROI calculation requires understanding where HPC creates value in the pipeline. The technology is not a single tool but a category of infrastructure that enables specific computationally intensive tasks that would be impractical or prohibitively slow on standard hardware.
Molecular Dynamics Simulation
Molecular dynamics (MD) simulation models how drug molecules interact with protein targets at the atomic level over time. These simulations require processing the physical behaviour of thousands to hundreds of thousands of atoms simultaneously — a task that scales directly with compute power. The practical value is significant: MD simulation enables researchers to predict how tightly a candidate molecule will bind to its target, model the conformational changes proteins undergo during binding, and identify off-target interactions that might create toxicity problems before a compound ever enters a lab. Researchers at the University of Melbourne and Oak Ridge National Laboratory demonstrated in 2024 that exascale HPC systems can now model biological systems at quantum-level accuracy, enabling molecular behaviour prediction at a scale that sets a new benchmark for computational chemistry.
Virtual Screening of Compound Libraries
Virtual screening uses HPC to computationally test millions of compounds against a specific protein target, identifying candidates worth synthesizing and testing physically. Traditional high-throughput screening (HTS) requires synthesizing and physically assaying each compound — a process that is both expensive and time-consuming. Virtual screening on HPC infrastructure allows researchers to screen compound libraries numbering in the millions within hours or days rather than months, at a fraction of the cost of physical screening. The AI in drug discovery market reflects this shift: the global market was valued at $19.89 billion in 2025 and is projected to reach $133.92 billion by 2034, growing at a compound annual rate of 23.22% — driven substantially by computational screening workloads running on HPC infrastructure.
Protein Structure Prediction
DeepMind’s AlphaFold 2 and AlphaFold 3 represent the most visible example of HPC-enabled protein structure prediction at scale. The AlphaFold database now contains approximately 200 million predicted protein structures, each requiring substantial GPU computation to generate. For drug discovery teams, accurate protein structure prediction is foundational — knowing the three-dimensional shape of a disease target determines which compound classes are worth screening and how to design molecules with optimal binding profiles. Running these models at research scale requires multi-GPU cluster infrastructure, either on-premises or through cloud HPC providers.
Genomics and Proteomics Data Processing
Next-generation sequencing generates datasets on a scale that standard computational infrastructure cannot process in clinically relevant timeframes. HPC systems handle genome assembly, variant calling, RNA-seq analysis, and proteomics workflows at the throughput needed for translational research. For biotech organizations working in precision medicine, oncology, or rare disease, the ability to process patient-level genomic data rapidly is a direct competitive advantage and a prerequisite for personalized therapeutic development.
How to Build the HPC ROI Framework for Biotech
The ROI calculation for HPC investment in a biotech or pharmaceutical context differs from standard IT ROI because the returns are distributed across a multi-year drug development timeline rather than appearing in quarterly operational savings. A rigorous framework needs to capture both direct cost avoidance and pipeline value acceleration.
Cost Avoidance: Reducing Wet Lab Expenditure
The most direct ROI metric is the reduction in physical lab costs through computational pre-screening. Every compound that fails in silico rather than in vitro or in vivo avoids synthesis costs, reagent costs, assay costs, and researcher time. For large-compound virtual screens, the ratio of computationally eliminated candidates to physically tested candidates determines the direct cost avoidance. A well-run HPC-powered virtual screen that filters 10 million compounds down to 500 high-confidence candidates before any physical work begins can avoid tens of millions of dollars in synthesis and screening costs at scale.
Cloud HPC provider Fovus has documented cases where AI-optimized cloud HPC reduced a research team’s monthly cloud spend from $20,000 to $5,000 — a 75% reduction — while accelerating time-to-insight from weeks to hours. The mechanism is workload-aware resource allocation: matching compute intensity to the right instance types rather than running fixed-size clusters regardless of job requirements.
Timeline Acceleration: Compressing the Discovery Phase
Drug development timelines are directly tied to capital costs through the cost of capital on R&D investment. Every month removed from the pre-clinical timeline reduces the cumulative capital required to reach a value inflection point. The compounding effect of timeline compression on NPV is substantial — particularly for oncology and rare disease programs where first-mover advantage affects pricing power and market share.
The data on HPC-enabled timeline compression is compelling. Recursion Pharmaceuticals moved a cancer candidate from discovery to clinical trials in 18 months, compared to a 42-month industry norm — a reduction enabled by AI and HPC-accelerated target identification and compound optimization. Insilico Medicine designed its idiopathic pulmonary fibrosis candidate INS018/055 from target identification to clinical candidate in approximately 18 months at a reported computational cost of roughly $150,000, versus the typical five to six years and tens of millions of dollars for conventional approaches. That timeline compression implies an ROI on the HPC infrastructure investment that is difficult to replicate through any other operational lever.
Pipeline Value: Improving Lead Quality
Beyond cost and timeline, HPC-powered discovery improves the quality of candidates entering expensive clinical stages. Higher-quality leads — better binding affinity, stronger selectivity, cleaner safety profiles identified computationally — translate directly into higher Phase 1 and Phase 2 success rates. Given that Phase 1 success rates have dropped to 6.7% across the industry, even modest improvements in lead quality produce significant pipeline value. The global drug discovery market is projected to reach $174.14 billion by 2035, and organizations that can demonstrate superior computational lead optimization have a structural advantage in attracting partnership capital and achieving favorable licensing terms.
The deployment of automated systems in life sciences operations follows the same ROI logic: the upfront infrastructure investment is justified by compounding operational advantages over a multi-year horizon, and the alternative — manual processes — becomes progressively less competitive as automation capability improves.
On-Premises HPC vs Cloud HPC: ROI Implications
The infrastructure decision between on-premises HPC clusters and cloud HPC directly affects the ROI calculation and risk profile of the investment.
On-Premises HPC
On-premises HPC delivers the lowest per-job compute cost at sustained utilization rates above 70–80%. For large pharma organizations with consistent, predictable computational workloads running year-round — continuous MD simulation campaigns, large-scale virtual screening programs, ongoing genomics processing — dedicated on-premises infrastructure typically offers the best long-term cost structure. The tradeoff is capital expenditure intensity, long procurement and deployment timelines, and limited flexibility to burst capacity for peak demand periods. Depreciation schedules of three to five years also mean that technology generations turn over slower than cloud infrastructure.
Cloud HPC
Cloud HPC has become the dominant choice for early-stage biotech companies and for pharma organizations that experience highly variable computational demand. The model eliminates capital expenditure on hardware, allows scaling to arbitrary cluster sizes for peak workloads, and provides access to the latest GPU generations without hardware refresh cycles. For virtual screening campaigns that might require tens of thousands of GPUs for a 48-hour run followed by minimal compute demand, cloud HPC economics are significantly superior to on-premises. The emergence of outcome-based pricing models from providers like Viridien — where costs align with research outcomes rather than raw consumption — further strengthens the cloud ROI case for discovery-stage organizations.
Hybrid Approaches
The HPE and AMD framework presented at HIMSS 2025 articulated the emerging consensus: a hybrid HPC environment that uses on-premises capacity for baseline computational workloads and cloud burst capacity for peak demand provides the best balance of cost efficiency and flexibility. The optimal split depends on average versus peak utilization — organizations with high average utilization benefit from shifting the baseline on-premises, while those with highly variable demand keep more in cloud. The practical outcome, as HPE described it, is a hybrid environment that reduces R&D timelines, controls expenses, and accelerates time to discovery simultaneously.
Key HPC Platforms and Tools in Drug Discovery
Understanding which platforms are used in production drug discovery environments helps biotech organizations make informed infrastructure and partnership decisions.
Schrödinger
Schrödinger’s physics-based drug design platform is the most widely used commercial HPC-dependent tool in the pharmaceutical industry. Its FEP+ (free energy perturbation) workflow for lead optimization requires substantial HPC resources but delivers binding affinity predictions accurate enough to guide medicinal chemistry decisions with confidence. Schrödinger’s platform is used by virtually every major pharma company for late-stage lead optimization and is the benchmark for physics-based computational chemistry in commercial settings.
AMBER and GROMACS
AMBER and GROMACS are the dominant open-source molecular dynamics packages in academic and biotech research environments. Both are optimized for GPU-accelerated computation and scale efficiently across multi-node HPC clusters. GROMACS in particular has become a standard workload for HPC benchmarking in life sciences because of its wide adoption and well-characterized scaling behaviour.
SeeSAR and HPSee (BioSolveIT)
BioSolveIT’s HPSee integrates with the SeeSAR platform to provide a user-facing interface for executing large-scale virtual screening campaigns on HPC infrastructure. The platform handles workflow management and result analysis within a single environment, reducing the IT overhead associated with running distributed HPC screening jobs. It targets the practical bottleneck that many computational biologists face: deep domain expertise without the infrastructure management skills needed to efficiently run HPC workloads at scale.
Quantori HPC Accelerators
Quantori’s HPC accelerator platform targets biotech organizations that need production-scale HPC without building internal IT capability. The platform covers genomics, CryoEM, computational chemistry, and machine learning workloads through a unified interface, with docking factory tools specifically designed for structure-based drug design. The value proposition aligns with the broader pattern in the industry: domain scientists need to run computation at scale without becoming HPC administrators.
Measuring HPC ROI in Practice: Metrics That Matter
Defining the right metrics is critical to making the ROI case for HPC investment internally and to investors. Generic IT ROI metrics — cost per compute hour, hardware utilization rates — do not capture the science-driven value that HPC creates in drug discovery. The metrics that carry weight are those that connect computational investment to pipeline outcomes.
Cost Per Lead Identified
The total cost of HPC infrastructure and cloud spend divided by the number of qualified leads identified and advanced into hit-to-lead chemistry. This metric normalizes infrastructure cost against scientific productivity and captures the efficiency gain from virtual screening relative to physical screening campaigns.
Time From Target to Clinical Candidate
The number of months from validated target identification to clinical candidate nomination. HPC investment should compress this metric measurably. Benchmarking against the industry norm of five to six years for conventional approaches provides a clear before/after comparison when AI and HPC-enabled workflows are adopted.
Phase Transition Rates for HPC-Enabled Programs
The proportion of HPC-enabled discovery programs that advance from hit to lead, lead to candidate, and candidate to IND. If computationally optimized leads advance through the pipeline at higher rates than historically observed — reflecting better binding affinity, selectivity, and safety profiles — that improvement directly validates the ROI of the HPC investment. The governance frameworks around AI training systems apply here too: the quality of computational predictions is only as strong as the training data and validation protocols behind the models generating them.
Reduction in Physical Assay Costs
Total physical assay spend before and after implementing HPC-powered virtual screening. Documenting the reduction in wet lab expenditure per program provides a concrete dollar figure that finance teams and investors can evaluate directly against infrastructure costs.
Common Pitfalls in HPC ROI Assessments for Biotech
Several recurring errors undermine HPC ROI analyses in biotech organizations, leading either to underinvestment that slows pipeline development or overinvestment in infrastructure that sits underutilized.
Underestimating data management costs is the most common mistake. HPC-generated datasets from MD simulation and virtual screening campaigns are massive — petabyte-scale storage requirements are normal for active programs. Organizations that focus the ROI calculation on compute costs alone and underbudget for storage, data transfer, and data management infrastructure consistently find their actual costs significantly above projections.
Evaluating HPC in isolation from the scientific workflow it enables leads to poor utilization. HPC infrastructure that is not tightly integrated with the computational chemistry and bioinformatics tools the research team actually uses produces low utilization rates and weak returns. The technology investment and the scientific workflow design need to be co-developed — infrastructure procurement without workflow redesign rarely captures the ROI potential.
Using peak compute hours as the primary utilization metric creates a distorted picture of cost efficiency. Drug discovery HPC workloads are inherently bursty — a virtual screening campaign might consume a large cluster for 72 hours, followed by weeks of minimal activity. Measuring utilization at the campaign level rather than calendar month level gives a more accurate picture of whether infrastructure is appropriately sized for the organization’s actual scientific output.
Ignoring talent costs in the ROI model understates the true investment. Running HPC workloads at the scale needed for drug discovery requires computational scientists and research IT specialists who command significant salaries in the current market. Cloud HPC managed service models address this by absorbing the infrastructure management burden, but the staff cost of in-house HPC operations is a material line item that belongs in any honest ROI assessment.
The AI Acceleration Layer and Its Impact on HPC ROI
The convergence of AI and HPC has changed the ROI calculation for drug discovery infrastructure in ways that are still working through the industry. AI models — particularly deep generative models for molecule design, graph neural networks for property prediction, and large language models for literature mining — dramatically increase the value of HPC infrastructure by enabling workloads that were not possible five years ago.
The AI in drug discovery sector has raised over $420 billion in disclosed funding globally, with more than 530 companies active in the space as of late 2025. The AI-based drug discovery approach is estimated to save approximately 70% of costs for pharmaceutical and biotech companies in target programs where it is fully implemented. That cost reduction figure compounds with HPC efficiency gains — faster compute at lower cost per job, combined with better AI models that require fewer iteration cycles to reach a quality candidate. The investment landscape around AI infrastructure reflects this convergence: capital is flowing toward organizations that combine computational capability with deep domain expertise, because that combination is producing measurably better pipeline outcomes than either element alone.
The AlphaFold paradigm illustrates the trajectory. Protein structure prediction that required years of experimental work and cost hundreds of thousands of dollars per structure in the pre-AlphaFold era now runs in hours on GPU clusters. The downstream effect on drug discovery is that target identification and structure-based design decisions that previously required years of structural biology work can now be made at the start of a program — compressing the entire pipeline and improving target selection quality simultaneously.
Frequently Asked Questions
What is a realistic HPC ROI timeline for a drug discovery organization?
For cloud HPC deployments with strong scientific workflow integration, productivity gains typically appear within six to twelve months as virtual screening campaigns reduce physical assay spend and timeline compression becomes measurable. On-premises HPC ROI horizons are longer — typically three to five years — because of capital expenditure amortization. Early-stage biotechs generally realize faster ROI through cloud HPC because they avoid capital allocation to infrastructure that competes with pipeline funding.
How does HPC investment affect fundraising and valuation for biotech startups?
Investors increasingly assess computational capability as a core component of a biotech’s platform valuation. Demonstrating HPC-enabled lead identification speed and cost efficiency — supported by data on time from target to candidate and cost per lead — strengthens the platform story and supports higher valuation multiples than organizations relying solely on wet-lab pipelines. The ability to show measurable timeline compression relative to industry benchmarks is particularly persuasive in current fundraising environments where capital efficiency is heavily scrutinized.
What size of biotech organization justifies dedicated on-premises HPC?
Organizations running continuous computational workloads across multiple simultaneous programs — typically mid-size to large pharma or well-funded clinical-stage biotechs — justify dedicated on-premises HPC when projected utilization exceeds 70% on an annual basis. Below that threshold, cloud HPC almost always offers better economics due to the capital cost and operational overhead of dedicated clusters. Early-stage discovery biotechs should default to cloud HPC until their computational demand profile becomes predictable enough to justify on-premises investment.
How does Eroom’s Law affect the HPC ROI calculation?
Eroom’s Law observes that drug discovery has become progressively slower and more expensive over time despite technology advances — the inverse of Moore’s Law. HPC and AI represent the most credible available counter to Eroom’s Law by substituting computational cycles for physical experiments in the early pipeline. The ROI case for HPC should be framed against the baseline cost of Eroom’s Law trajectories — without computational acceleration, development costs and timelines will continue to inflate. HPC investment is not just an efficiency gain; it is a structural defense against the rising cost baseline of conventional drug development.
What are the key differences between HPC requirements for small molecule and biologics discovery?
Small molecule discovery workloads are dominated by virtual screening and MD simulation — both highly parallel workloads that scale well on GPU clusters and benefit directly from raw compute throughput. Biologics discovery, including antibody design and protein engineering, involves larger molecular systems, more complex simulation requirements, and heavier reliance on cryo-EM data processing and protein structure prediction pipelines. Biologics workloads typically require more memory per compute node and place greater demands on storage infrastructure for cryo-EM image datasets. Both benefit from HPC investment, but the infrastructure profile for a biologics-focused organization differs meaningfully from a small molecule operation.
Conclusion
The ROI case for HPC in drug discovery is no longer speculative — it is documented in timelines, cost structures, and pipeline outcomes from organizations across the industry. The convergence of increasingly capable AI models with cloud and on-premises HPC infrastructure has created a computational environment where early drug discovery can be conducted at a fraction of the historical cost and timeline, with lead quality that improves rather than degrades the further into the pipeline programs advance.
Organizations evaluating HPC investment should build their ROI framework around the metrics that connect compute spending to pipeline outcomes: cost per lead identified, time from target to clinical candidate, Phase transition rates, and physical assay cost reduction. Generic IT cost metrics fail to capture the scientific value that HPC creates. The organizations extracting the strongest returns are those that co-design HPC infrastructure investment with scientific workflow redesign — treating computational capability as a core R&D asset rather than a supporting IT function.
The financial environment for drug development continues to tighten, with Phase 1 success rates at decade lows and development costs exceeding $2 billion per approved asset. HPC-enabled discovery is the most scalable available response to those pressures — and the gap between organizations with strong computational capability and those without it will continue to widen as AI model quality and HPC infrastructure efficiency improve.
